Related Experiment Videos
[Methicillin-resistant staphylococcal enterocolitis developed after induction chemotherapy in a case of acute
Abstract:
A case of methicillin-resistant staphylococcal (MRSA) enterocolitis following combination chemotherapy for acute promyelocytic leukemia is presented. MRSA enterocolitis has characteristic clinical features of high fever, frequent vomiting and watery diarrhea, and its mortality rate is very high without a proper antibiotic therapy. When the patient with hematological malignancy has the above-mentioned clinical manifestations during antineoplastic chemotherapy, appropriate antibiotics for MRSA should be promptly begun before a bacteriological diagnosis.
Insights
A case of methicillin-resistant Staphylococcus aureus (MRSA) enterocolitis occurred after chemotherapy for acute promyelocytic leukemia. Prompt MRSA antibiotic treatment is crucial for patients with hematological malignancies presenting with fever, vomiting, and diarrhea.
Area of Science:
- Hematology
- Infectious Diseases
- Oncology
Background:
- Acute promyelocytic leukemia (APL) treatment often involves combination chemotherapy.
- Hematological malignancies increase susceptibility to opportunistic infections.
- Enterocolitis is a serious gastrointestinal complication.
Observation:
- A patient undergoing chemotherapy for APL developed methicillin-resistant Staphylococcus aureus (MRSA) enterocolitis.
- Clinical presentation included high fever, persistent vomiting, and watery diarrhea.
- This condition carries a high mortality rate if not treated promptly.
Findings:
- MRSA enterocolitis requires specific antibiotic therapy.
- Early empirical antibiotic administration is vital in immunocompromised patients with suggestive symptoms.
- Bacteriological diagnosis may be delayed, necessitating prompt clinical management.
Implications:
- Highlights the importance of early recognition and management of MRSA enterocolitis in chemotherapy patients.
- Suggests empirical antibiotic treatment for MRSA should be considered in patients with hematological malignancies presenting with severe gastrointestinal symptoms during chemotherapy.
- Underscores the need for vigilance regarding infectious complications in immunocompromised individuals undergoing intensive cancer treatment.